New drug aims to spare cancer patients from debilitating mouth sores
NCT ID NCT05966194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. The main goal is to see if RRx-001 reduces the number of patients who develop severe mouth sores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RRx-001
What this could lead to
If it works, this could provide a way to prevent severe mouth sores during cancer treatment, improving quality of life for head and neck cancer patients.
What could go wrong
This is a mid-stage trial with 216 participants, so results are not yet proven. The drug may not reduce mouth sores more than placebo, and side effects from the drug itself are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL MUCOSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ballad Health
Johnson City, Tennessee, 37604, United States
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
East Carolina University School of Medicine
Greenville, North Carolina, 27834, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Parkview Cancer Institute
Fort Wayne, Indiana, 46845, United States
-
Renown Regional Medical Center
Reno, Nevada, 89502, United States
-
Sandra and Malcolm Berman Cancer Institute
Baltimore, Maryland, 21204, United States
-
The Ohio State University James Cancer Hospital & Solove Research Institute
Columbus, Ohio, 43210, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Willis Knighton Cancer Center
Shreveport, Louisiana, 71103, United States